Opinion|Videos|July 9, 2024
Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
- How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
5